1,3-Diethyl-indol | 16885-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,3-Diethyl-indol
• 英文别名: 1,3-Diethyl indole；1,3-diethylindole
• CAS: 16885-92-0
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: QSSPQNFFJWBCPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,3-Diethyl-indol 、 2-(hydroxy(phenyl)methyl)phenol 在 C₄₃H₆₂Br₂N₄O₄ 、 lithium bromide 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 四氢呋喃 为溶剂， 反应 72.5h， 以90%的产率得到(S)-2-((1,3-diethyl-1H-indol-2-yl)(phenyl)methyl)phenol
  参考文献：
  名称：

  手性N，N'-二氧化–（III）络合物催化邻羟基苄醇与C3取代的N-保护的吲哚的不对称Friedel-Crafts烷基化反应

  摘要：

  描述了第一个路易斯酸催化邻羟基苄醇与C3取代的吲哚的不对称Friedel-Crafts烷基化反应。手性N，N'-二氧化物Sc（OTf）3配合物不仅可促进原位形成邻醌甲基（o- QMs），而且可引起反应的不对称性。该方法可实现邻羟基苯甲醇的新型活化，从而以高达99％的收率和99％ee的产率提供所需的手性二芳基吲哚-2-基甲烷。在温和的反应条件下，还可以耐受一系列官能团。此外，该策略使获得富含对映体的吲哚稠合苯并氧还酮的方法更为简便。

  DOI：

  10.1002/chem.201604088
• 作为产物：
  描述：

  1-乙基-1-苯肼 在 2-丁烯腈 、 palladium 10% on activated carbon 、 zinc(II) chloride 作用下， 以 2-甲基-2-丁醇 、 甲苯 为溶剂， 反应 15.0h， 生成 1,3-Diethyl-indol
  参考文献：
  名称：

  钯催化的胺类脱氢生成胺。通过胺与芳肼的交叉偶联反应获得吲哚的自然路线

  摘要：

  AbstractH‐substituted imines are elusive compounds formed when aldehydes or ketones are mixed with ammonia. However, this class of molecules can be prepared through selective removal of a hydrogen molecule from a primary amine using a transition metal catalyst. This biomimetic transformation, previously employed for the N‐alkylation of anilines, is applied here to a domino preparation of differently substituted indoles from aliphatic primary amines and arylhydrazines. Several different linear and branched aliphatic primary amines are oxidized with reusable palladium on charcoal to the corresponding primary imines entrapped as arylhydrazones that can be isolated as such. Arylhydrazones can be further converted into N‐alkylindole derivatives via an acid‐mediated indolisation reaction. The one‐pot domino hydrogen transfer Fischer indole synthesis under heterogeneous catalysis is also possible, giving access to diverse substituted indoles, including NH indoles obtained after deprotection of the corresponding benzyl compounds. The truly heterogeneous nature of the catalyst was demonstrated by recycling the catalyst in the same reaction, and in other palladium‐catalysed transformations.magnified image

  DOI：

  10.1002/adsc.201300559

文献信息

• Ligands and libraries of ligands
  申请人：Wells Jim

  公开号：US20080261831A1

  公开（公告）日：2008-10-23

  The invention relates to variants of Target Biological Molecules (TBMs), such as proteins, peptides and other amino acid sequences that are modified to include cysteine residues at predetermined positions within the TBM. The position of amino acid residues within the TBM that are modified to be cysteine residues is selected for its proximity to ligand binding sites within the TBM. Once an amino acid residue, or the DNA encoding the residue, is modified to cysteine, the TBM linked to potential binding ligands by forming a covalent bond through the cysteine thiol (—SH) reactive group of the variant.

  本发明涉及靶生物分子（TBM）的变异体，例如蛋白质、肽和其他氨基酸序列，这些序列被修改以在TBM内的预定位置包括半胱氨酸残基。所选的氨基酸残基位置在TBM内被修改为半胱氨酸残基，是由于其靠近TBM内配体结合位点。一旦氨基酸残基或编码该残基的DNA被修改为半胱氨酸，TBM通过半胱氨酸巯基（—SH）反应基团形成共价键与潜在的结合配体相连。
• Piperazine compound as PAF-antagonist
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0243122A2

  公开（公告）日：1987-10-28

  A piperazine compound of the formula: wherein R' and R" are each hydrogen or lower alkyl, R1 is 1-(1-methylindol-3-yl)ethyl, 1-(1-ethylindol-3-yl)ethyl, 1-(1-propylindol-3-yl)ethyl, 1-(1,2-dimethylindol-3-yl)ethyl, 1-(1-methyl-2-phenylindol-3-yl)ethyl, 1-(1,5-dimethylindol-3-yl)ethyl, 1-(5-methyl-1-propylindol-3-yl)ethyl, 1-(2,5-dimethyl-1-propylindol-3-yl)ethyl, 1-(1,2,5-trimethylindol-3-yl)ethyl 1-(1-butyl-2-methylindol-3-yllethyl, 1-(1-isobutylindol-3-yl)ethyl, 1-(1-methylindol-3-yl)propyl, 1-(1-ethyl-6-methylindol-3-yl)ethyl or 1-(1-ethyl-5-methylindol-3-yl)ethyl, R2 is 2-pyridylmethyl; or R1 is 1-methylindol-3-ylmethyl and R2 is 3-(or 4-)pyridylmethyl; or R1 is 1-naphthylmethyl and R2 is butyl or R1 is heterocyclic(lower)alkyl which may have one or more lower alkyl(s) on the heterocyclic ring and R2 is thiazolyl(lower)alkyl, quinolyl(tower)alkyl, tetahydropyridyl(lower)alkyl which may have lower alkyl on the tetrahydropyridine ring, or a group of the formula: wherein A is lower alkylene, R3 is lower alkyl and X is acid residue; or R1 is indolyl(lower)alkyl having lower alkyl and lower alkoxy on the indole ring, indolyl(lower)alkyl having one or more lower alkyl(s) and halogen on the indole ring, indolyl(lower)alkyl having lower alkyl and ar(lower)alkoxy on the indole ring or indolylar-(lower)alkyl having lower alkyl on the indole ring and R2 is heterocyclic(lower)alkyl, and pharmaceutically acceptable salt thereof, which are highly potent antagonists of PAF, processes for the preparation thereof and a pharmaceutical composition comprising the same.

  一种哌嗪化合物，其式如下 其中 R' 和 R" 均为氢或低级烷基、 R1 是 1-(1-甲基吲哚-3-基)乙基、 1-(1-乙基吲哚-3-基)乙基 1-(1-丙基吲哚-3-基)乙基 1-(1,2-二甲基吲哚-3-基)乙基、 1-(1-甲基-2-苯基吲哚-3-基)乙基 1-(1,5-二甲基吲哚-3-基)乙基 1-(5-甲基-1-丙基吲哚-3-基)乙基 1-(2,5-二甲基-1-丙基吲哚-3-基)乙基、 1-(1,2,5-三甲基吲哚-3-基)乙基 1-(1-丁基-2-甲基吲哚-3-基乙基) 1-(1-异丁基吲哚-3-基)乙基、 1-(1-甲基吲哚-3-基)丙基、 1-(1-乙基-6-甲基吲哚-3-基)乙基或 1-(1-乙基-5-甲基吲哚-3-基)乙基、 R2 是 2-吡啶甲基；或 R1 是 1-甲基吲哚-3-基甲基和 R2 是 3-（或 4-）吡啶基甲基；或 R1 是 1-萘甲基，R2 是丁基或萘甲基。 R2是丁基或 R1 是杂环（低级）烷基，杂环上可能有一个或多个低级烷基，且 R2 是噻唑基（低级）烷基、 喹啉基（塔）烷基、 四氢吡啶（低级）烷基（四氢吡啶环上可能有低级烷基）或式中的一个基团： 其中 A 为低级亚烷基、 R3 是低级烷基 X 是酸残基；或 R1 是在吲哚环上具有低级烷基和低级烷氧基的吲哚基(低级)烷基、在吲哚环上具有一个或多个低级烷基和卤素的吲哚基(低级)烷基、在吲哚环上具有低级烷基和ar(低级)烷氧基的吲哚基(低级)烷基或在吲哚环上具有低级烷基的吲哚基ar-(低级)烷基，以及 R2 是杂环（低级）烷基及其药学上可接受的盐，它们是 PAF 的强效拮抗剂，其制备方法和包含它们的药物组合物。
• Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof
  申请人：INVENTISBIO SHANGHAI LTD.

  公开号：US11203589B2

  公开（公告）日：2021-12-21

  The present invention disclosed a class of pyrimidine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor), and the growth of a variety of tumor cells effectively and can be used for the treatment, combined therapy or prevention of various different cancers, particularly for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶化合物、其药学上可接受的盐、立体异构体、原药和溶媒、其制备方法和药物组合物及其药物用途。见下文式 I 等。本发明化合物可有效抑制表皮生长因子受体（EGFR）的变体，抑制多种肿瘤细胞的生长，可用于各种不同癌症的治疗、联合治疗或预防，特别是用于治疗或预防由表皮生长因子受体变体（如L858R激活突变体、Exon19缺失激活突变体和T790M耐药突变体）介导的疾病、紊乱、失调或病症。
• Nishida, Takuo; Tokuda, Yoshikazu; Tsuchiya, Michihiro, Journal of the Chemical Society. Perkin transactions II, 1995, # 4, p. 823 - 830
  作者：Nishida, Takuo、Tokuda, Yoshikazu、Tsuchiya, Michihiro

  DOI：——

  日期：——
• Biswas, K M; Dhara, R N; Mallik, Haimanti, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 10, p. 906 - 910
  作者：Biswas, K M、Dhara, R N、Mallik, Haimanti、Halder, Sumita、Sinha-Chaudhuri, Arunima、et al.

  DOI：——

  日期：——